Iron metabolism in prostate cancer; from basic science to new therapeutic strategies
- 1University of Pristina, Albania
An increasing amount of research has recently strengthened the case for the existence of iron dysmetabolism in prostate cancer. It is characterized with a wide array of differential expression of iron-related proteins compared to normal cells. These proteins control iron entry, cellular iron distribution but also iron exit from prostate cells. Iron dysmetabolism is not an exclusive feature of prostate cancer cells, but it is observed in other cells of the tumor microenvironment. Disrupting the machinery that secures iron for prostate cancer cells can retard tumor growth and its invasive potential. This review unveils the current understanding of the ways that prostate cancer cells secure iron in the tumor milieu and how can we exploit this knowledge for therapeutic purposes.
Keywords: prostate cancer, iron metabolism, Transferrin receptor 1, iron responsive element-binding protein 2, Ferroportin, hepcidin, tumor associated macrophages, cancer stem cells
Received: 23 Sep 2018;
Accepted: 05 Nov 2018.
Edited by:Justin Lathia, Cleveland Clinic Lerner College of Medicine, United States
Reviewed by:James Connor, Penn State Milton S. Hershey Medical Center, United States
Daniel E. Frigo, University of Texas MD Anderson Cancer Center, United States
Copyright: © 2018 Vela. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Driton Vela, University of Pristina, Prishtina, Albania, firstname.lastname@example.org